Immunome (IMNM) Revenue (2023 - 2025)

Immunome (IMNM) has 3 years of Revenue data on file, last reported at $4.0 million in Q2 2025.

• For the quarter ending Q2 2025, Revenue rose 69.84% year-over-year to $4.0 million; the trailing twelve-month figure through Mar 2026 stood at $4.0 million (down 63.29% YoY), and the FY2025 full-year result was $6.9 million, down 23.23% from the prior year.
• Revenue for Q2 2025 stood at $4.0 million, up from $2.9 million in the prior quarter.
• Across five years, Revenue topped out at $4.3 million in Q2 2023 and bottomed at $1.0 million in Q1 2024.
• The 3-year median for Revenue is $2.9 million (2024), against an average of $3.0 million.
• The widest annual swing landed in 2024, when Revenue tumbled 56.47%; it then soared 184.35% in 2025.
• A 3-year view of Revenue shows it stood at $3.8 million in 2023, then dropped by 28.44% to $2.7 million in 2024, then soared by 46.64% to $4.0 million in 2025.
• The last three Revenue figures came in at $4.0 million (Q2 2025), $2.9 million (Q1 2025), and $2.7 million (Q4 2024), per Business Quant data.

Peer Comparison